Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Varese – page 94

2 655 clinical trials in Varese, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Varese at a glance
2 655
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 655 trials in Varese

Open in trial search

Clear cell renal cell carcinoma+2

Not yet recruiting

Phase 1/2 Study of pumitamig Alone or Combined with ipilimumab or cabozantinib in Patients with Advanced Renal Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Endometrial cancer

Not yet recruiting

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:GSK5733584
  • Sponsor:Glaxosmithkline Research & Development Limited

Choroid melanoma

Not yet recruiting

Long‑Term Follow‑Up Study of Belzupacap Sarotalocan in Patients with Early Choroidal Melanoma

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Aura Biosciences Inc.

Asthma

Not yet recruiting

Long‑Term Safety and Tolerability Study of Oral KT‑621 in Adults with Uncontrolled Moderate‑to‑Severe Eosinophilic Asthma

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:KT-621
  • Sponsor:Kymera Therapeutics Inc.

Gaucher's disease type III

Not yet recruiting

Efficacy and safety of oral venglustat versus intravenous imiglucerase in children aged 2‑11 years with Gaucher disease type 3

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Imiglucerase
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Metastatic renal cell carcinoma

Not yet recruiting

Comparison of nivolumab drug combination versus immunotherapy‑TKI sequence in patients with metastatic renal cell carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Optic ischaemic neuropathy

Not yet recruiting

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

A Phase III study of AZD0120 with drug combination versus standard therapy in adults with newly diagnosed multiple myeloma not eligible for stem cell transplant

Not yet recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:Astrazeneca AB

Spinal muscular atrophy

Not yet recruiting

Safety and Efficacy of Intrathecal BIIB115 in Infants with Spinal Muscular Atrophy Previously Treated with Onasemnogene Abeparvovec

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:BIIB115
  • Sponsor:Biogen Idec Research Limited

Stargardt's disease

Not yet recruiting

Phase 3 Study of Gildeuretinol Acetate (ALK‑001) to Assess Safety and Efficacy in Slowing Progression of Stargardt Disease in Adults

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Gildeuretinol acetate
  • Sponsor:Alkeus Pharmaceuticals Inc.

Hepatocellular carcinoma

Not yet recruiting

Advanced hepatocellular carcinoma patients: assessing atezolizumab drug combination and other treatment sequences

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Azienda Sanitaria Locale Napoli 1 Centro

Heart failure with reduced ejection fraction

Not yet recruiting

Evaluating the efficacy and safety of CRD-4730 in patients with heart failure with reduced ejection fraction

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:CRD-4730
  • Sponsor:Cardurion Pharmaceuticals Inc.

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Varese

What the registry says about research in the country

01 Hematologic Oncology

Groundbreaking research focusing on blood cancers and lymphomas, including studies of novel therapies for acute myeloid leukemia and chronic myeloid leukemia. Clinical trials are evaluating innovative treatment combinations and maintenance strategies.

  • Follicular Lymphoma Treatment Optimization
  • Leukemia Targeted Therapies
  • B-cell Lymphoma Management

Investigations include maintenance therapies and comparison of shortened versus standard chemotherapy protocols combined with immunotherapy.

02 Thoracic Oncology

Comprehensive studies on non-small cell lung cancer and pleural mesothelioma, exploring innovative combination therapies and targeted treatments for specific genetic mutations.

  • EGFR-TKI Sequencing Studies
  • Immunotherapy Combinations
  • Targeted Molecular Therapies

Research focuses on personalized treatment approaches and novel drug combinations to improve patient outcomes.

03 Cardiovascular Medicine

Advanced research in cardiovascular disease and thrombosis, with trials examining innovative treatments for reducing cardiovascular events and managing blood clots.

  • Lipoprotein Management
  • Deep Vein Thrombosis Treatment
  • Cardiovascular Risk Reduction

Studies aim to evaluate new therapeutic approaches for preventing major cardiovascular events and improving patient outcomes.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.